- Animalcare Group said Monday it expected earnings growth for the full would be flat compared to last year following delays to some new product launches and lower demand in the large animal portfolio.

'For the year ended 31 December 2018, the Board expects 2018 earnings (EBITDA) for the continuing Pharmaceuticals segment to be approximately in line with the prior year,' the company said.

Total revenue for the year ended 31 December increased by 3.6% to £84.2m. Excluding the wholesale business which was sold on 4 September 2018, sales from continuing Pharmaceuticals segment increased by 3.2% to £71.8m.

The focus during 2019 and beyond would be on five strategic priorities to help to boost growth and profitability while increasing operational effectiveness and efficiency.

The highlights of strategic priorities would include, driving supply chain efficiencies including associated working capital, increasing commercial capabilities to drive organic growth and reviewing the portfolio to focus resources on profitable growth, enhanced through in-licensing and M&A.

At 10:07am: [LON:ANCR] Animalcare Group PLC share price was -16.5p at 138.5p

Story provided by